On Monday, Larimar Therapeutics Inc (NASDAQ: LRMR) opened lower -4.86% from the last session, before settling in for the closing price of $3.91. Price fluctuations for LRMR have ranged from $1.61 to $9.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 50.78%. Company’s average yearly earnings per share was noted -26.93% at the time writing. With a float of $46.99 million, this company’s outstanding shares have now reached $64.03 million.
Let’s determine the extent of company efficiency that accounts for 65 employees.
Larimar Therapeutics Inc (LRMR) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Larimar Therapeutics Inc is 43.23%, while institutional ownership is 43.71%. The most recent insider transaction that took place on Jul 31 ’25, was worth 30,000,000. In this transaction Director of this company bought 9,375,000 shares at a rate of $3.20, taking the stock ownership to the 9,538,945 shares.
Larimar Therapeutics Inc (LRMR) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.24 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.37) by 0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -26.93% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.33% during the next five years compared to 50.78% growth over the previous five years of trading.
Larimar Therapeutics Inc (NASDAQ: LRMR) Trading Performance Indicators
Check out the current performance indicators for Larimar Therapeutics Inc (LRMR). In the past quarter, the stock posted a quick ratio of 5.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.56, a number that is poised to hit -0.41 in the next quarter and is forecasted to reach -1.73 in one year’s time.
Technical Analysis of Larimar Therapeutics Inc (LRMR)
Looking closely at Larimar Therapeutics Inc (NASDAQ: LRMR), its last 5-days average volume was 1.38 million, which is a jump from its year-to-date volume of 1.09 million. As of the previous 9 days, the stock’s Stochastic %D was 29.26%.
During the past 100 days, Larimar Therapeutics Inc’s (LRMR) raw stochastic average was set at 75.36%, which indicates a significant increase from 30.65% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.35 in the past 14 days, which was higher than the 0.27 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.39, while its 200-day Moving Average is $3.55. However, in the short run, Larimar Therapeutics Inc’s stock first resistance to watch stands at $3.88. Second resistance stands at $4.03. The third major resistance level sits at $4.12. If the price goes on to break the first support level at $3.64, it is likely to go to the next support level at $3.55. Should the price break the second support level, the third support level stands at $3.40.
Larimar Therapeutics Inc (NASDAQ: LRMR) Key Stats
There are currently 82,778K shares outstanding in the company with a market cap of 307.94 million. Presently, the company’s annual sales total 0 K according to its annual income of -80,600 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -26,180 K.